The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified

1. Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer 2019; 19: 273. doi: 10.1186/s12885-019-5466-y QiuL ZhengH ZhaoX The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis BMC Cancer 2019 19 273 10.1186/s12885-019-5466-y Open DOISearch in Google Scholar

2. Minghan Q, Shan W, Xinrui C, Huaqing W. Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting. Cancer Biol Med 2022; 19: 1117–20. doi: 10.20892/j.issn.2095-3941.2022.0403 MinghanQ ShanW XinruiC HuaqingW Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting Cancer Biol Med 2022 19 1117 20 10.20892/j.issn.2095-3941.2022.0403 Open DOISearch in Google Scholar

3. Wang C, Shi F, Liu Y, Zhang Y, Dong L, Li X, et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. J Hematol Oncol 2021; 14: 106. doi: 10.1186/s13045-021-01120-3 WangC ShiF LiuY ZhangY DongL LiX Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy J Hematol Oncol 2021 14 106 10.1186/s13045-021-01120-3 Open DOISearch in Google Scholar

4. Lu T, Zhang J, Xu-Monette ZY, Young KH. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp Hematol Oncol 2023; 12: 72. doi: 10.1186/s40164-023-00432-z LuT ZhangJ Xu-MonetteZY YoungKH The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma Exp Hematol Oncol 2023 12 72 10.1186/s40164-023-00432-z Open DOISearch in Google Scholar

5. Guan J, Zhang J, Zhang X, Yuan Z, Cheng J, Chen B. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. Medicine 2022; 101: e32333. doi: 10.1097/MD.0000000000032333 GuanJ ZhangJ ZhangX YuanZ ChengJ ChenB Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials Medicine 2022 101 e32333 10.1097/MD.0000000000032333 Open DOISearch in Google Scholar

6. Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol 2019; 77: 105999. doi: 10.1016/j.intimp.2019.105999 XieM HuangX YeX QianW Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma Int Immunopharmacol 2019 77 105999 10.1016/j.intimp.2019.105999 Open DOISearch in Google Scholar

7. Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A. Neoadjuvant immunotherapy: A promising new standard of care. Int J Mol Sci 2023; 24: 11849. doi: 10.3390/ijms241411849 BoydellE SandovalJL MichielinO ObeidM AddeoA FriedlaenderA Neoadjuvant immunotherapy: A promising new standard of care Int J Mol Sci 2023 24 11849 10.3390/ijms241411849 Open DOISearch in Google Scholar

8. Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer 2017; 36: 94. doi: 10.1186/s40880-017-0262-z HuLY XuXL RaoHL ChenJ LaiRC HuangHQ Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study Chin J Cancer 2017 36 94 10.1186/s40880-017-0262-z Open DOISearch in Google Scholar

9. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2017; 14: 203–20. doi: 10.1038/nrclinonc.2016.168 GoodmanA PatelSP KurzrockR PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas Nat Rev Clin Oncol 2017 14 203 20 10.1038/nrclinonc.2016.168 Open DOISearch in Google Scholar

10. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology 2017;152: 357–71. doi: 10.1111/imm.12788 JelinekT MihalyovaJ KascakM DurasJ HajekR PD-1/PD-L1 inhibitors in haematological malignancies: update 2017 Immunology 2017 152 357 71 10.1111/imm.12788 Open DOISearch in Google Scholar

11. Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 2017; 10: 103. doi: 10.1186/s13045-017-0474-3 OkCY YoungKH Checkpoint inhibitors in hematological malignancies J Hematol Oncol 2017 10 103 10.1186/s13045-017-0474-3 Open DOISearch in Google Scholar

12. Wang Y, Wu L, Tian C, Zhang Y. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann Hematol 2018; 97: 229–37. doi: 10.1007/s00277-017-3176-6 WangY WuL TianC ZhangY PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas Ann Hematol 2018 97 229 37 10.1007/s00277-017-3176-6 Open DOISearch in Google Scholar

13. Annibali O, Crescenzi A, Tomarchio V, Pagano A, Bianchi A, Grifoni A, et al. PD-1 /PD-L1 checkpoint in hematological malignancies. Leuk Res 2018; 67: 45–55. doi: 10.1016/j.leukres.2018.01.014 AnnibaliO CrescenziA TomarchioV PaganoA BianchiA GrifoniA PD-1 /PD-L1 checkpoint in hematological malignancies Leuk Res 2018 67 45 55 10.1016/j.leukres.2018.01.014 Open DOISearch in Google Scholar

14. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015; 126: 2193–201. doi: 10.1182/blood-2015-02-629600 KiyasuJ MiyoshiH HirataA ArakawaF IchikawaA NiinoD Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma Blood 2015 126 2193 201 10.1182/blood-2015-02-629600 Open DOISearch in Google Scholar

15. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, WHO classification of tumours, Revised 4th edition, Volume 2. France: International Agency for Research on Cancer; 2017. SwerdlowSH CampoE HarrisNL JaffeES PileriSA SteinH WHO classification of tumours of haematopoietic and lymphoid tissues, WHO classification of tumours Revised 4th edition 2 France International Agency for Research on Cancer 2017 Search in Google Scholar

16. Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, et al. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine 2017; 96: e6398. doi: 10.1097/MD.0000000000006398 FangX XiuB YangZ QiuW ZhangL ZhangS The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma Medicine 2017 96 e6398 10.1097/MD.0000000000006398 Open DOISearch in Google Scholar

17. Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 2016; 68: 1079–89. doi: 10.1111/his.12882 KwonD KimS KimPJ GoH NamSJ PaikJH Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas Histopathology 2016 68 1079 89 10.1111/his.12882 Open DOISearch in Google Scholar

18. Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, et al. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 2017; 8: 44960–75. doi: 10.18632/oncotarget.16680 GravelleP BurroniB PéricartS RossiC BezombesC TosoliniM Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies Oncotarget 2017 8 44960 75 10.18632/oncotarget.16680 Open DOISearch in Google Scholar

19. Zeng Q, Liu Z, Liu T. Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. BMC Cancer 2020; 20: 59. doi: 10.1186/s12885-020-6550-z ZengQ LiuZ LiuT Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis BMC Cancer 2020 20 59 10.1186/s12885-020-6550-z Open DOISearch in Google Scholar

20. Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 pathway and Its blockade in patients with classic Hodgkin lymphoma and Non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep 2020; 15: 372–81. doi: 10.1007/s11899-020-00589-y XieW MedeirosLJ LiS YinCC KhouryJD XuJ PD-1/PD-L1 pathway and Its blockade in patients with classic Hodgkin lymphoma and Non-Hodgkin large-cell lymphomas Curr Hematol Malig Rep 2020 15 372 81 10.1007/s11899-020-00589-y Open DOISearch in Google Scholar

21. Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016; 7: 59976–86. doi: 10.18632/oncotarget.11045 XingW DresserK ZhangR EvensAM YuH WodaBA ChenBJ PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications Oncotarget 2016 7 59976 86 10.18632/oncotarget.11045 Open DOISearch in Google Scholar

22. Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H: The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007; 31: 1579–83. doi: 10.1016/j.leukres.2007.03.017 ShiozawaE Yamochi-OnizukaT TakimotoM OtaH The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries Leuk Res 2007 31 1579 83 10.1016/j.leukres.2007.03.017 Open DOISearch in Google Scholar

23. Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010; 29: 47–53. doi: 10.3233/DMA-2010-0725 MuenstS HoellerS WilliN DirnhoferaS TzankovA Diagnostic and prognostic utility of PD-1 in B cell lymphomas Dis Markers 2010 29 47 53 10.3233/DMA-2010-0725 Open DOISearch in Google Scholar

24. Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin’s lymphomas. Oncoimmunology 2015; 4: e1026530. doi: 10.1080/2162402X.2015.1026530 LaurentC CharmpiK GravelleP TosoliniM FranchetC YsebaertL Several immune escape patterns in non-Hodgkin’s lymphomas Oncoimmunology 2015 4 e1026530 10.1080/2162402X.2015.1026530 Open DOISearch in Google Scholar

25. Karakatsanis S, S Papadatos S, Syrigos N, Marinos L, Pouliou E, Papanikolaou A. Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings. J BUON 2021; 26: 569–79. KarakatsanisS S PapadatosS SyrigosN MarinosL PouliouE PapanikolaouA Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings J BUON 2021 26 569 79 Search in Google Scholar

26. Desouki MM, Post GR, Cherry D, Lazarchick J. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res 2010; 8: 84–8. doi: 10.3121/cmr.2010.891 DesoukiMM PostGR CherryD LazarchickJ PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms Clin Med Res 2010 8 84 8 10.3121/cmr.2010.891 Open DOISearch in Google Scholar

27. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–82. doi: 10.1182/blood-2003-05-1545 HansCP WeisenburgerDD GreinerTC GascoyneRD DelabieJ OttG Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 2004 103 275 82 10.1182/blood-2003-05-1545 Open DOISearch in Google Scholar

28. Boltezar L, Kloboves-Prevodnik V, Pohar-Perme M, Gasljevic G, Jezersek-Novakovic B. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15: 6903–12. doi: 10.3892/ol.2018.8243 BoltezarL Kloboves-PrevodnikV Pohar-PermeM GasljevicG Jezersek-NovakovicB Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma Oncol Lett 2018 15 6903 12 10.3892/ol.2018.8243 Open DOISearch in Google Scholar

29. Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget 2019; 10: 2030–40. doi: 10.18632/oncotarget.26771 ChenBJ DashnamoorthyR GaleraP MakarenkoV ChangH GhoshS The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma Oncotarget 2019 10 2030 40 10.18632/oncotarget.26771 Open DOISearch in Google Scholar

30. Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res 2019; 7: 644–57. doi: 10.1158/2326-6066.CIR-18-0439 Xu-MonetteZY XiaoM AuQ PadmanabhanR XuB HoeN Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL Cancer Immunol Res 2019 7 644 57 10.1158/2326-6066.CIR-18-0439 Open DOISearch in Google Scholar

31. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–94. doi: 10.1056/NEJM199309303291402 International Non-Hodgkin’s Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin’s lymphoma N Engl J Med 1993 329 987 94 10.1056/NEJM199309303291402 Open DOISearch in Google Scholar

32. McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 2019; 3: 531–40. doi: 10.1182/bloodadvances.2018020602 McCordR BolenCR KoeppenH KadelEE3rd OestergaardMZ NielsenT PD-L1 and tumor-associated macrophages in de novo DLBCL Blood Adv 2019 3 531 40 10.1182/bloodadvances.2018020602 Open DOISearch in Google Scholar

33. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–73. doi: 10.1158/1078-0432.CCR-13-0855 ChenBJ ChapuyB OuyangJ SunHH RoemerMG XuML PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies Clin Cancer Res 2013 19 3462 73 10.1158/1078-0432.CCR-13-0855 Open DOISearch in Google Scholar

34. Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 2016; 7: 73068–79. doi: 10.18632/oncotarget.12230 ZhangT XieJ AraiS WangL ShiX ShiN The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis Oncotarget 2016 7 73068 79 10.18632/oncotarget.12230 Open DOISearch in Google Scholar

35. Kwon HJ, Yang JM, Lee JO, Lee JS, Paik JH. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. J Transl Med 2018; 16: 320. doi: 10.1186/s12967-018-1689-y KwonHJ YangJM LeeJO LeeJS PaikJH Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma J Transl Med 2018 16 320 10.1186/s12967-018-1689-y Open DOISearch in Google Scholar